Takeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume

Takeda Pharmaceutical Company Limited (NYSE:TAKGet Rating) shares saw an uptick in trading volume on Monday . 204,186 shares changed hands during trading, a decline of 92% from the previous session’s volume of 2,633,736 shares.The stock last traded at $13.26 and had previously closed at $13.45.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on TAK. Jefferies Financial Group cut shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, July 29th. Cowen raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Tuesday, July 19th. Finally, Cowen raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $21.00 to $24.00 in a research report on Tuesday, July 19th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $24.00.

Takeda Pharmaceutical Price Performance

The company’s 50-day moving average is $14.01 and its 200-day moving average is $14.25. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.18 and a quick ratio of 0.75. The firm has a market capitalization of $40.99 billion, a price-to-earnings ratio of 24.94, a PEG ratio of 0.55 and a beta of 0.70.

Takeda Pharmaceutical (NYSE:TAKGet Rating) last released its earnings results on Thursday, July 28th. The company reported $0.56 earnings per share (EPS) for the quarter. The business had revenue of $7.51 billion for the quarter. Takeda Pharmaceutical had a net margin of 5.43% and a return on equity of 12.41%. On average, research analysts expect that Takeda Pharmaceutical Company Limited will post 2.25 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Private Capital Group LLC lifted its position in Takeda Pharmaceutical by 79.8% during the first quarter. Private Capital Group LLC now owns 1,865 shares of the company’s stock valued at $27,000 after buying an additional 828 shares in the last quarter. Herold Advisors Inc. acquired a new position in Takeda Pharmaceutical during the first quarter valued at approximately $29,000. Ronald Blue Trust Inc. acquired a new position in Takeda Pharmaceutical during the second quarter valued at approximately $34,000. Northwestern Mutual Wealth Management Co. lifted its position in Takeda Pharmaceutical by 217.8% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,730 shares of the company’s stock valued at $39,000 after buying an additional 1,871 shares in the last quarter. Finally, Addison Advisors LLC acquired a new position in Takeda Pharmaceutical during the first quarter valued at approximately $48,000. 1.96% of the stock is owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

(Get Rating)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience.

Further Reading

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Takeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume

Takeda Pharmaceutical Company Limited (NYSE:TAKGet Rating) shares saw an uptick in trading volume on Monday . 204,186 shares changed hands during trading, a decline of 92% from the previous session’s volume of 2,633,736 shares.The stock last traded at $13.26 and had previously closed at $13.45.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on TAK. Cowen raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $21.00 to $24.00 in a research note on Tuesday, July 19th. Cowen raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Tuesday, July 19th. Finally, Jefferies Financial Group cut shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, July 29th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $24.00.

Takeda Pharmaceutical Price Performance

The firm has a market capitalization of $40.99 billion, a price-to-earnings ratio of 24.94, a PEG ratio of 0.55 and a beta of 0.70. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.18 and a quick ratio of 0.75. The company’s 50-day moving average is $14.01 and its 200-day moving average is $14.25.

Takeda Pharmaceutical (NYSE:TAKGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.56 earnings per share for the quarter. The firm had revenue of $7.51 billion for the quarter. Takeda Pharmaceutical had a net margin of 5.43% and a return on equity of 12.41%. On average, research analysts expect that Takeda Pharmaceutical Company Limited will post 2.25 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Private Capital Group LLC lifted its position in Takeda Pharmaceutical by 79.8% during the first quarter. Private Capital Group LLC now owns 1,865 shares of the company’s stock valued at $27,000 after buying an additional 828 shares in the last quarter. Herold Advisors Inc. acquired a new position in Takeda Pharmaceutical during the first quarter valued at approximately $29,000. Ronald Blue Trust Inc. acquired a new position in Takeda Pharmaceutical during the second quarter valued at approximately $34,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Takeda Pharmaceutical by 217.8% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,730 shares of the company’s stock valued at $39,000 after purchasing an additional 1,871 shares during the period. Finally, Addison Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the first quarter valued at approximately $48,000. 1.96% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

(Get Rating)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience.

Further Reading

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.